Improvements seen in blood pressure and central and peripheral aortic stiffness and pressure hemodynamics in teens with type 1 diabetes<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Dec. 6, 2022 (HealthDay News) — For adolescents with type 1 diabetes (T1D), bromocriptine quick release (BCQR) improves blood pressure and central and peripheral aortic stiffness, according to a study published online Dec. 6 in Hypertension<\/em>.<\/p>\n Michal Sch \u00a4fer, M.D., from the University of Colorado School of Medicine in Aurora, and colleagues examined the cardiovascular and metabolic impact of BCQR in youth with T1D. Thirty-four adolescents with T1D were randomly assigned in a 1:1 ratio to four weeks of BCQR or placebo during phase 1; after this phase, blood pressure and central aortic stiffness measurements by pulse wave velocity, relative area change, and distensibility from phase-contrast magnetic resonance imaging were performed. Phase 2 was conducted in an identical manner with the alternate treatment after a four-week washout.<\/p>\n The researchers found that BCQR therapy reduced systolic and diastolic blood pressure (\u00ce\u0094 = \u00e2\u0088\u00925 and \u00e2\u0088\u00922 mm Hg, respectively) compared with placebo. The ascending aortic pulse wave velocity was reduced with BCQR (\u00ce\u0094 = \u00e2\u0088\u00920.4 m\/s), and relative area change and distensibility increased (\u00ce\u0094 = \u00e2\u0088\u00922.6 percent and 0.008 percent\/mm Hg, respectively). BCQR reduced pulse wave velocity (\u00ce\u0094 = \u00e2\u0088\u00920.2 m\/s) and increased distensibility (\u00ce\u0094 = 0.05 percent\/mm Hg) in the thoraco-abdominal aorta.<\/p>\n “A stiff aorta predisposes a patient to other health issues, such as organ dysfunction or atherosclerosis and higher stress or strain on cardiac muscle,” Sch \u00a4fer said in a statement. “We were able to take it a notch further and show, using more sophisticated metrics, that these central large arteries are impaired, and impairment among adolescents and young adults with type 1 diabetes may be decelerated with this drug.”<\/p>\n Two authors disclosed financial ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n